Ardelyx (ARDX) : The money flow analysis of Ardelyx (ARDX) indicates a $0.1 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $0.66 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 6.38 and so was the total money flow at $0.55 million. The bulls lapped up $0.52 million worth of block trades on upticks. The money flow was $0.52 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Ardelyx (ARDX), pushing it down by -2.62% for the day. The stock slid $0.27 and traded at $10.05 during the day. Nonetheless, the stock is -2.9% over the previous weeks close.
The company Insiders own 15.46% of Ardelyx shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 9.56% . Institutional Investors own 62.84% of Ardelyx shares. During last six month period, the net percent change held by insiders has seen a change of 9.56%.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director 10% owner of Ardelyx, Inc., Mott David M, had purchased 1,527,301 shares in a transaction dated on July 18, 2016. The transaction was executed at $8.73 per share with total amount equaling $13,333,338.
Ardelyx (NASDAQ:ARDX): stock was range-bound between the intraday low of $9.9708 and the intraday high of $10.41 after having opened at $10.32 on Fridays session. The stock finally closed in the red at $10.32, a loss of -0.87%. The stock remained in the red for the whole trading day. The total traded volume was 208,736 shares. The stock failed to cross $10.41 in Fridays trading. The stocks closing price on Thursday was $10.32.
Ardelyx (ARDX) : During the past 4 weeks, traders have been relatively bearish on Ardelyx (ARDX), hence the stock is down -0.26% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.66% relative to the S&P 500. The 4-week change in the price of the stock is -0.39% and the stock has fallen -1.16% in the past 1 week.
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal (GI) tract to treat cardio-renal, GI and metabolic diseases. The Company utilizing its platform, discovered and designed its lead product candidate, tenapanor, which in clinical studies has demonstrated the ability to improve the symptoms of constipation-predominant irritable bowel syndrome (IBS-C) and to reduce the absorption of both dietary sodium and phosphorus. The Company in collaboration with AstraZeneca, has completed a Phase IIb clinical trial evaluating tenapanor in patients with IBS-C. It also has other product candidates under development, such as RDX002 for the treatment of Hyperphosphatemia, RDX009 for the treatment of IBD, Short Bowel Syndrome and non-alcoholic steatohepatitis (NASH), and RDX013 for the treatment of hyperkalemia.